Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Morning! Today, we have a deep probe into Moderna’s travails from STAT’s tireless Jason Mast. Also, a pharma bidding war, thoughts on psychedelic regulation, and the Trump administartion is trying to fast-track cheaper biosimilars.

The need-to-know this morning

A new drug-sales king has been crowned. Eli Lilly’s diabetes and weight-loss drug tirzepatide, marketed under the Mounjaro and Zepbound brand names, delivered $10.1 billion in third-quarter sales. Tirzepatide’s quarterly sales surpassed the $8.1 billion in sales from Merck’s cancer immunotherapy blockbuster Keytruda for the first time.

More earnings from Bristol Myers Squibb , Biogen , Insmed

See Full Page